This video is entirely AI generated and does not replicate any original material. It should not be considered a substitute for authentic sources. For complete context and techniques, viewers are encouraged to refer to the original content.
Based on findings from:
-
Next-generation AI for visually occult pancreatic cancer detection in a low-prevalence setting with longitudinal stability and multi-institutional generalisability
Sovanlal Mukherjee, et al.. Gut, 2026.
DOI: 10.1136/gutjnl-2025-337266
-
FDA Announces Major Steps to Implement Real-Time Clinical Trials
-
Diagnostic accuracy, fairness and clinical implementation of AI for breast cancer screening: results of multicenter retrospective and prospective technical feasibility studies
Christopher Kelly, et al. Nature Cancer, 2026.
DOI: 10.1038/s43018-026-01127-0
-
Impact of using artificial intelligence as a second reader in breast screening including arbitration
Lucy Warren, et al.. Nature Cancer, 2026.
DOI: 10.1038/s43018-026-01128-z
Weekly News Brief: May 4–8, 2026
To catch up on all of the news from this past week, listen to our weekly news brief for the week of May 4–8, 2026.
This week’s brief covers an AI framework for early pancreatic cancer detection, FDA using AI to accelerate clinical trials, and two studies assessing integration of AI into the UK mammography workflow.
To learn more about REDMOD for pancreatic cancer detection, read "Automated AI Framework Paves Way for Earlier Detection of Pancreatic Ductal Adenocarcinoma," or see the source report in Gut.
For more information on the FDA's AI use, read "FDA Explores AI to Accelerate Early-Phase Clinical Trials in Pilot Program," or see the FDA's announcement.
To learn more about the AIMS project studies, read "Two Studies Demonstrate Real-World Feasibility and Accuracy of AI-Integrated Breast Cancer Screening," or see the source reports in Nature Cancer.
Disclaimer: This newscast was generated with the assistance of AI tools and avatars. All content is reviewed and approved by the editorial staff of ASCO AI in Oncology. Contact us with any questions.
The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. The mention of any company, product, service, or therapy should not be construed as an endorsement of any kind. Conexiant and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of material contained in this publication or to any errors or omissions.